Oshagbemi, Olorunfemi A.
Lopez-Romero, Pedro
Winnips, Cornelis
Csermak, Katalin R.
Su, Guoqin
Aubrun, Elodie
Funding for this research was provided by:
Novartis pharma AG, Basel, Switzerland
Article History
Received: 24 August 2023
Accepted: 29 November 2023
First Online: 5 December 2023
Declarations
:
: This study was conducted in accordance with the 18th World Medical Assembly (Helsinki) recommendations and amendments, as well as guidelines for Good Epidemiology Practice. The study protocol was approved by the institutional review boards and independent ethics committees at all participating study locations; each site ensured all necessary regulatory submissions in accordance with local regulations including local data protection regulations. All patients provided informed, written consent according to local independent review board ruling.
: Written informed consent was obtained from the patients’ guardians for their anonymized information to be published in this article.
: All authors are Novartis employees and own shares in the company.